References:
1. Levine, S. (2008) NEJM; 358(13): 1327-1355. doi: 10.1056/NEJMoa070447; Dres, M. (2017) Am J Respir Crit Care Med; 195(1): 57-66. doi: 10.1164/rccm.201602-0367OC
2. Dres, M. (2025) Am J Resp Crit Care Med:. doi: 10.1164/rccm.202505-1056OC – Per-protocol (>50% of required stimulations) data for the AeroPace group relative to the Control group.
Who is the AeroPace System for?
The AeroPace System is indicated to improve weaning success – increase weaning, reduce ventilator days, and reduce reintubation – in patients ages 18 years or older on mechanical ventilation ≥ 96 hours and who have not weaned.
Do not use the AeroPace System with active implanted cardiac pacemakers, defibrillators, or other implantable electronics within proximity to the AeroPace Neurostimulation Catheter. The AeroPace System has not been clinically evaluated for safety with these implantable electronic devices.